News

GvHD is a potentially life-threatening medical complication, which can affect patients receiving such transplants to treat certain genetic diseases and haematologic cancers. Orencia is an immunomodulator that disturbs

The transaction has been taken up by AstraZeneca as the compound patent protection of the two drugs is no longer valid in the two countries. It would also

Bristol-Myers Squibb Company (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee will hold a review

The agreement is to generate and optimise antibodies for novel immuno-oncology targets, including access to IONTAS’ proprietary Mammalian Display technology to select antibodies with optimal biophysical properties. IONTAS’

The approval has been granted for Tecentriq in combination with Abraxane (paclitaxel protein-bound; nab-paclitaxel) and carboplatin for the first-line treatment of adults with metastatic NSCLC with no EGFR

As part of the deal, STADA will also acquire Biopharma’s two GMP-certified production facilities in the city of Bila Tserkva, Kiev. The shareholders of Biopharma will retain the

The 52-week, randomized, double-blind, placebo-controlled trial will evaluate whether dexpramipexole is associated with a reduction in asthma exacerbations. Fifteen severe asthma centers across the United Kingdom (UK) will

PHALCON-EE is a randomized, double-blind, two-phase, multicenter Phase 3 trial that is planned to enroll approximately 1,000 patients with EE in the U.S. and Europe. The first phase

Under the deal, Astellas US Holding wholly-owned subsidiary Asilomar Acquisition will acquire Audentes by paying $60 per share in cash. Audentes chairman and CEO Matthew Patterson said: “With